MAPP Share Price

Open 25.01 Change Price %
High 25.01 1 Day -0.02 -0.08
Low 24.98 1 Week 0.00 0.00
Close 24.98 1 Month 0.00 0.00
Volume 1080194 1 Year 0.00 0.00
52 Week High 45.00
52 Week Low 25.76
MAPP Important Levels
Resistance 2 25.01
Resistance 1 25.00
Pivot 24.99
Support 1 24.96
Support 2 24.95
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

MAP Pharmaceuticals, Inc. (NASDAQ: MAPP)

MAPP Technical Analysis 5
As on 1st Mar 2013 MAPP Share Price closed @ 24.98 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.48 & Strong Buy for SHORT-TERM with Stoploss of 20.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
MAPP Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
MAPP Other Details
Segment EQ
Market Capital 541194880.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
MAPP Address
MAPP
N/A
MAPP Latest News
Interactive Technical Analysis Chart MAP Pharmaceuticals, Inc. ( MAPP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on MAP Pharmaceuticals, Inc.
MAPP Business Profile
MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.